Literature DB >> 11526184

Heteroresistance to vancomycin in Enterococcus faecium.

M R Alam1, S Donabedian, W Brown, J Gordon, J W Chow, M J Zervos, E Hershberger.   

Abstract

This study presents the first report of vancomycin heteroresistance in an Enterococcus faecium isolate from a patient. The original isolate was susceptible in vitro to vancomycin. E-tests showed growth of subcolonies in a zone of inhibition with a vancomycin MIC of >256 microg/ml. Both the susceptible and resistant colonies were from the same strain as determined by PFGE, and both contained the vanA gene as determined by PCR.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11526184      PMCID： PMC88352          DOI： 10.1128/JCM.39.9.3379-3381.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Identification and characterization of IS1476, an insertion sequence-like element that disrupts VanY function in a vancomycin-resistant Enterococcus faecium strain.

Authors:  M G MacKinnon; M A Drebot; G J Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 2.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

3.  PCR fragment length polymorphism analysis of vancomycin-resistant Enterococcus faecium.

Authors:  S Donabedian; E Hershberger; L A Thal; J W Chow; D B Clewell; B Robinson-Dunn; M J Zervos
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

4.  Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.

Authors:  T L Smith; M L Pearson; K R Wilcox; C Cruz; M V Lancaster; B Robinson-Dunn; F C Tenover; M J Zervos; J D Band; E White; W R Jarvis
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

5.  Predominant pathogens in hospital infections.

Authors:  W R Jarvis; W J Martone
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

6.  Major trends in the microbial etiology of nosocomial infection.

Authors:  D R Schaberg; D H Culver; R P Gaynes
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

7.  Addressing emerging infectious disease threats: a prevention strategy for the United States. Executive summary.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1994-04-15

8.  Molecular analysis of glycopeptide-resistant Enterococcus faecium isolates collected from Michigan hospitals over a 6-year period.

Authors:  L Thal; S Donabedian; B Robinson-Dunn; J W Chow; L Dembry; D B Clewell; D Alshab; M J Zervos
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

9.  Characterization of glycopeptide-resistant enterococci from U.S. hospitals.

Authors:  N C Clark; R C Cooksey; B C Hill; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group.

Authors:  R N Jones; H S Sader; M E Erwin; S C Anderson
Journal:  Diagn Microbiol Infect Dis       Date:  1995-02       Impact factor: 2.803
View more
  12 in total

1.  Heteroresistance to teicoplanin in Enterococcus faecium harboring the vanA gene.

Authors:  Ting-ting Qu; Jun-li Zhang; Zhi-hui Zhou; Ze-qing Wei; Yun-song Yu; Ya-gang Chen; Lan-juan Li
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

Review 2.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

3.  Heteroresistance to cephalosporins and penicillins in Acinetobacter baumannii.

Authors:  Kuei-Hsiang Hung; Ming-Cheng Wang; Ay-Huey Huang; Jing-Jou Yan; Jiunn-Jong Wu
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

4.  Endocarditis caused by resistant enterococcus: an overview.

Authors:  Katherine Reyes; Marcus Zervos
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

5.  A low-affinity penicillin-binding protein 2x variant is required for heteroresistance in Streptococcus pneumoniae.

Authors:  Hansjürg Engel; Moana Mika; Dalia Denapaite; Regine Hakenbeck; Kathrin Mühlemann; Manfred Heller; Lucy J Hathaway; Markus Hilty
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

6.  Vancomycin-variable Enterococcus faecium: in vivo emergence of vancomycin resistance in a vancomycin-susceptible isolate.

Authors:  Bryan Coburn; Donald E Low; Samir N Patel; Susan M Poutanen; Dea Shahinas; Alireza Eshaghi; Barbara M Willey; Allison McGeer
Journal:  J Clin Microbiol       Date:  2014-02-12       Impact factor: 5.948

7.  Heteroresistance to penicillin in Streptococcus pneumoniae.

Authors:  Brigitte Morand; Kathrin Mühlemann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-17       Impact factor: 11.205

8.  Prevalence and detection of mixed-population enterococcal bacteremia.

Authors:  Ana María Cárdenas; Kathleen A Andreacchio; Paul H Edelstein
Journal:  J Clin Microbiol       Date:  2014-05-14       Impact factor: 5.948

9.  Heteroresistance to fosfomycin is predominant in Streptococcus pneumoniae and depends on the murA1 gene.

Authors:  Hansjürg Engel; Javier Gutiérrez-Fernández; Christine Flückiger; Martín Martínez-Ripoll; Kathrin Mühlemann; Juan A Hermoso; Markus Hilty; Lucy J Hathaway
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

10.  Co-existence of multidrug-resistant and -susceptible strains of Pseudomonas aeruginosa from a single clinical isolate.

Authors:  Krishna Mahida; Dong H Kwon
Journal:  Curr Microbiol       Date:  2009-12-29       Impact factor: 2.188
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.